Please assess the completion status of the following clinical trial:

Trial Title: Comparative Bioavailability of Myfenax® and CellCept® in Kidney Transplant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Renal transplant recipients at least 12 months post-transplantation aged ≥ 18 years.~* Maintenance treatment with mycophenolate mofetil (in combination with tacrolimus with or without corticosteroids).~* Stable dose of mycophenolate mofetil (≥ 500 mg twice daily) with no changes in immunosuppressive regimen for at least 6 weeks prior to the start of the study.~* Stable renal graft function for at least 3 months.~* Female patients must be either post-menopausal for ≥ 1 year, be surgically sterilized or a negative pregnancy test will be required immediately prior to study entry and such patients must continue to use effective contraception.~* Willingness to undergo the study-related procedures.~* Ability to comprehend and willingness to sign informed consent form.~Exclusion Criteria:~* History of allergy to mycophenolate mofetil, mycophenolic acid or any of the ingredients.~* Multi-organ recipients (e.g., kidney and pancreas) or previous transplant with any organ other than kidney.~* Rejection within the past 6 months prior to the start of the study.~* Severe clinically relevant co-existing disease.~* History of cancer other than skin cancer that has been cured.~* History of serious clinically relevant digestive system disease during the last 12 months prior to start of the study.~* Known or suspected hereditary deficiency of hypoxanthine-guanine-phosphoribosyltransferase (e.g., Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome).~* Known or suspected liver impairment.~* Clinically significant thrombocytopenia, anaemia, leukopenia, or neutropenia~* Clinically significant laboratory and/or physical changes during the last 2 months prior to the start of the study.~* Use of azathioprine, cholestyramine, sevelamer, or probenecid within 2 weeks prior to the first administration of study medication.~* Change in concomitant medication during the 6 weeks prior to start of the study.~* Use of any drug, prescribed or over-the-counter, (except stable concomitant medication) within 2 weeks prior to the first administration of study medication.~* Planned or expected requirement for the use of live attenuated vaccines during the study.~* Positive testing for HIV, Hepatitis B and C.~* Clinical symptoms or laboratory evidence of cytomegalovirus infection in the last 6 month.~* Pregnant or breast-feeding women.~* Women of childbearing potential unable or unwilling to practice effective contraceptive measures for the duration of the study and for 6 weeks after the end of the study.~* History of known or suspected alcohol or drug abuse.~* Any other condition of the patient that, in the opinion of the investigator may compromise evaluation of the study treatment or may jeopardize patient's compliance or adherence to protocol requirements.~* Previous enrollment in this study or participation in any other drug investigational trial within the past 6 weeks prior to enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Reference/Test/Test (Type: EXPERIMENTAL): The reference product was CellCept® and test product was Myfenax®. In period I, participants received CellCept on Days 1-14. In period II, participants crossed-over to receive Myfenax on Days 15-28. In period III, participants received Myfenax until the end of the study (Days 29-112).~Doses of mycophenolate mofetil were at least 500 mg twice daily, morning and evening.
- Test/Reference/Reference (Type: EXPERIMENTAL): The test product was Myfenax® and the reference product was CellCept®. In period I, participants received Myfenax on Days 1-14. In period II, participants crossed-over to receive CellCept on Days 15-28. In period III, participants received CellCept until the end of the study (Days 29-112).~Doses of mycophenolate mofetil were at least 500 mg twice daily, morning and evening.

Based on this trial design, predict the completion outcome and termination type (if applicable).